MONDAY, July 18 (HealthDay News) -- Since their advent in the
mid-1990s, powerful antiretroviral therapies have radically
improved the life expectancy of HIV-infected patients in the
Now, research suggests that when made affordable and accessible,
the same drug cocktails are equally effective for African
The finding stems from a Canadian research team's investigation
-- deemed the largest of its kind to date -- looking at HIV
treatment efforts in Uganda. They found that HIV-infected Ugandan
patients placed on combination antiretroviral therapy (cART) can
expect the same life expectancy as Ugandans who are free of the
"HIV/AIDS has historically been a death sentence in Africa," said study co-author Edward J. Mills, the Canada Research Chair in Global Health at the University of Ottawa. "But now we know that effective therapies, provided in a simplified and decentralized manner, can offer very favorable treatment effects in the African context in terms of reducing mortality and improving life expectancy."
Based on other recent studies, "we also now know that even in a
resource-poor environment such as Africa, these treatments can
actually prevent the spread of new infections to other people,"
His team released their findings online July 18 in advance of
publication in the Aug. 16 print issue of the
Annals of Internal Medicine.
The authors noted that the current life expectancy for Ugandans
who are not infected with HIV hovers around 55 years of age, a
figure that trends upwards as residents age.
According to the study, about 200,000 HIV-positive Ugandans are
currently on a cART regimen, while an equal number are waiting for
To assess the effectiveness of cART in helping HIV-infected
Ugandans achieve a longer life span, the authors focused on more
than 22,000 HIV patients aged 14 or older who were being cared for
at one of 46 different medical facilities across the country.
All of the patients had been first placed on an antiretroviral
regimen at some point between 2000 and 2009, and all were tracked
through February 2010.
Basic demographic information was collected, including the
patient's age when cART was initiated; year of initiation; patient
gender; and each patient's disease stage and clinical status at
By the study's conclusion, an estimated 1,943 patients had died.
Nevertheless, the investigators found that Uganda's antiretroviral
patients could generally expect to live just as long as
Specifically, that meant that HIV-positive Ugandans on a cART
regimen were found to have a life expectancy of somewhere between
about 47 and 63 years.
Not all patients fared equally well, of course. For example,
life expectancy among Ugandan cART patients diverged greatly
according to gender, with female patients living significantly
longer than male patients. While a 20-year-old Ugandan woman on
cART could expect to live until she was about 50, similarly aged
men were expected to survive to roughly 40. For 35-year-old cART
patients, those figures rose to about 68 years for women but just
57 years among men.
Why the gender disparity? The authors theorize that in Uganda,
HIV-positive women are quicker to seek medical care for their
situation than men. As happens in the developed world, the team
found that Ugandans who began their antiretroviral routine sooner
after diagnosis (typically with less advanced disease) lived
For his part, Dr. Jeffrey Laurence, a professor of medicine and
director of the Laboratory for AIDS Virus Research at the Weill
Medical College of Cornell University in New York City, described
the findings as "really good news."
"We've known for quite some time that life expectancy for HIV patients in resource-rich countries is enormously improved by these medications," said Laurence, who is also the senior scientist for programs at The Foundation for AIDS Research (amfAR). "But, the question has always been could you reproduce this elsewhere? And now we've found that in places such as Uganda, adherence can be very good. People can follow directions and adhere to their medications as well as they can in wealthier countries. And that's wonderful."
Uganda has been in the forefront of African nations in terms of
how active their government is in promoting HIV prevention and
treatment, Laurence acknowledged. But, "it's still a very poor
country in the middle of Africa," he said. "So it is very
heartening to see that this is working in the context."
"The challenge now is to sustain this spectacular success," said Dr. David Bangsberg, director of the Massachusetts General Hospital Center for Global Health in Boston.
"That will be
very challenging," he noted. "And that is because the therapy
is so effective. Because if these patients will now have a normal
life expectancy, you have to care for them for another 20 to 30
years, while other people are still becoming infected and adding to
the list of those who need this treatment. So, resources become a
bigger and bigger question, and gaps in treatment can develop," he
"So I would say that even though there has been enormous success so far, we're really at a crossroads," Bangsberg cautioned. "Now we have to see if we are able to sustain this success down the road."
For more on global antiretroviral therapy statistics, visit the
World Health Organization.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.